SeekingAlpha · Jul 24, 2026
NovoCure: Why I'm Fading The Q2 Earnings Rally
NovoCure stock remains a Hold: Q2 revenue rose 16% and EBITDA guidance improved, but cash generation lags. Click to read my analysis.
NV
NASDAQ · NVCR
NovoCure Limited
Healthcare · Medical - Instruments & Supplies
$17.59
Up+$0.10 (+0.55%)
Updated Aug 13, 2026, 7:11 PM
SID Score
6.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.53B
- P/E ratio
- -8.6
- Dividend yield
- 0.00%
- 52-week range
- $10.14 – $21.45
- Volume
- 1.18M
- Avg. volume
- 1.71M
Price performance
NVCR price history
1M range · 21 trading sessions · Daily adjusted prices
NVCR closed at $17.59 after 21 trading sessions, up 9.73% for the selected period.
- Last close
- $17.59
- Period change
- +9.73%
- Period low
- $14.84
- Period high
- $19.99
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $17.66 | $17.675 | $17.22 | $17.59 | 1.18M |
| Aug 11, 2026 | $17.34 | $17.8255 | $17.29 | $17.66 | 923.86K |
| Aug 10, 2026 | $16.27 | $17.59 | $16.27 | $17.31 | 1.05M |
| Aug 7, 2026 | $15.60 | $16.42 | $15.60 | $16.39 | 1.53M |
| Aug 6, 2026 | $16.20 | $16.20 | $15.58 | $15.69 | 943.32K |
| Aug 5, 2026 | $16.14 | $16.25 | $15.925 | $16.05 | 1.23M |
| Aug 4, 2026 | $15.28 | $16.30 | $15.23 | $16.27 | 1.74M |
| Aug 3, 2026 | $15.00 | $15.69 | $15.00 | $15.32 | 1.64M |
| Jul 31, 2026 | $15.46 | $15.725 | $14.83 | $14.84 | 1.23M |
| Jul 30, 2026 | $15.20 | $15.49 | $15.045 | $15.23 | 1.41M |
| Jul 29, 2026 | $16.06 | $16.39 | $15.12 | $15.20 | 1.51M |
| Jul 28, 2026 | $16.99 | $17.05 | $16.155 | $16.31 | 1.38M |
| Jul 27, 2026 | $17.97 | $18.15 | $16.855 | $17.03 | 1.81M |
| Jul 24, 2026 | $20.68 | $21.4506 | $17.60 | $17.65 | 3.88M |
| Jul 23, 2026 | $18.00 | $20.55 | $18.00 | $19.99 | 8.95M |
| Jul 22, 2026 | $15.99 | $16.125 | $15.20 | $15.57 | 1.06M |
| Jul 21, 2026 | $15.91 | $16.41 | $15.84 | $16.00 | 1.07M |
| Jul 20, 2026 | $16.00 | $16.19 | $15.795 | $15.94 | 933.51K |
| Jul 17, 2026 | $16.08 | $16.5199 | $15.8318 | $15.92 | 856.32K |
| Jul 16, 2026 | $16.05 | $16.525 | $16.03 | $16.42 | 1.12M |
| Jul 15, 2026 | $15.52 | $16.06 | $15.31 | $16.03 | 1.1M |
Latest NVCR news
The latest Smart Investors Daily articles mentioning NVCR.
Stock researchCompany · Overview
NVCR research
Overview
Company profile and research snapshot.
Company profile
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $28.25
- Implied upside
- —
- Analysts
- 13
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 24, 2026 | Wedbush | Neutral | — |
| Jul 23, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 13, 2026 | JP Morgan | Neutral | — |
| Jun 18, 2026 | HC Wainwright & Co. | Buy | — |
| May 4, 2026 | Wells Fargo | Equal-Weight | — |
News briefing
No generated briefing is available yet.
Benzinga · Jul 24, 2026
NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding
NovoCure revenue outlook rises after a Q2 beat, stronger patient growth, pipeline progress and planned trial savings.
SeekingAlpha · Jul 24, 2026
NovoCure's Clean Beat Signals A Shift Toward Profitability (Rating Upgrade)
Novocure (NVCR) beats 2Q26, raises guidance and posts positive adj. EBITDA.
Benzinga · Jul 24, 2026
Wedbush Maintains Neutral on NovoCure, Raises Price Target to $20
Wedbush analyst David Nierengarten maintains NovoCure (NASDAQ:NVCR) with a Neutral and raises the price target from $18 to $20.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
